Evidence map›Paper›PMID 25748205›Full record

ArticleThe Biochemical journal2015

Solution structure of the reduced form of human peroxiredoxin-6 elucidated using zero-length chemical cross-linking and homology modelling.

Roland F Rivera-Santiago, Sandra L Harper, Suiping Zhou, Sira Sriswasdi, Sheldon I Feinstein, Aron B Fisher, David W Speicher

Open access · greenAbstract read
In one paragraph

Article in The Biochemical journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Peroxiredoxins in Cancer and Response to Radiation Therapies.Antioxidants (Basel, Switzerland) · 2019
    Review
  5. Article
  6. The phospholipase AJournal of lipid research · 2018
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Roland F Rivera-Santiago*The Center for Systems and Computational Biology, The Wistar Institute and Molecular and Cellular Oncogenesis, Philadelphia, PA 19104, U.S.A.
Sandra L Harper*The Center for Systems and Computational Biology, The Wistar Institute and Molecular and Cellular Oncogenesis, Philadelphia, PA 19104, U.S.A.
Suiping Zhou‡Institute for Environmental Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, U.S.A.
Sira Sriswasdi*The Center for Systems and Computational Biology, The Wistar Institute and Molecular and Cellular Oncogenesis, Philadelphia, PA 19104, U.S.A.
Sheldon I Feinstein‡Institute for Environmental Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, U.S.A.
Aron B Fisher‡Institute for Environmental Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, U.S.A.
David W Speicher*The Center for Systems and Computational Biology, The Wistar Institute and Molecular and Cellular Oncogenesis, Philadelphia, PA 19104, U.S.A.
The University of Tokyo · JP

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Joseph M Salvino · 1985 to 2026
$75.9M
STRUCTURAL BIOLOGY TRAINING PROGRAMT32GM008275 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI WAND, A. JOSHUA · 1988 to 2018
$6.0M
Role of Peroxiredoxin 6 in the Repair of Peroxidized Cell MembranesR01HL102016 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI FISHER, ARON B. · 2010 to 2018
$4.6M
Role of Prdx6 in the activation of NADPH oxidaseR01HL105509 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI FISHER, ARON B. · 2011 to 2015
$2.6M
REDOX REGULATION OF METABOLISM IN HYPOXIC DIAPHRAGMF32HL010216 · NHLBI · UPSTATE MEDICAL UNIVERSITY · PI KLAWITTER, PAUL F · 2000 to 2002
$150k
NCI NIH HHS CA10815NCI NIH HHS P30 CA010815NHLBI NIH HHS F32 HL010216NHLBI NIH HHS HL10216NHLBI NIH HHS R01 HL102016NHLBI NIH HHS R01 HL105509NIGMS NIH HHS T32 GM008275
6 · The paper itself

Abstract

Peroxiredoxin-6 (PRDX6) is an unusual member of the peroxiredoxin family of antioxidant enzymes that has only one evolutionarily conserved cysteine. It reduces oxidized lipids and reactive oxygen species (ROS) by oxidation of the active-site cysteine (Cys(47)) to a sulfenic acid, but the mechanism for conversion back to a thiol is not completely understood. Moreover, it has phospholipase A2 (PLA2) activity in addition to its peroxidase activity. Interestingly, some biochemical data are inconsistent with a known high-resolution crystal structure of the catalytic intermediate of the protein, and biophysical data indicate that the protein undergoes conformational changes that affect enzyme activity. In order to further elucidate the solution structure of this important enzyme, we used chemical cross-linking coupled with high-resolution MS (CX-MS), with an emphasis on zero-length cross-links. Distance constraints from high confidence cross-links were used in homology modelling experiments to determine a solution structure of the reduced form of the protein. This structure was further evaluated using chemical cross-links produced by several homo-bifunctional amine-reactive cross-linking reagents, which helped to confirm the solution structure. The results show that several regions of the reduced version of human PRDX6 are in a substantially different conformation from that shown for the crystal structure of the peroxidase catalytic intermediate. The differences between these two structures are likely to reflect catalysis-related conformational changes. These studies also demonstrate that CX-MS using zero-length cross-linking is a powerful strategy for probing protein conformational changes that is complementary to alternative methods such as crystallographic, NMR and biophysical studies.

Indexed as

Amino Acid SequenceCross-Linking ReagentsCrystallography, X-RayHumansModels, MolecularMolecular Sequence DataOxidation-ReductionPeroxiredoxin VIProtein ConformationProtein Structure, QuaternaryRecombinant ProteinsStructural Homology, ProteinTandem Mass SpectrometryCross-Linking ReagentsPeroxiredoxin VIPRDX6 protein, humanRecombinant Proteins

Identifiers

PMID25748205
PMCPMC4420655
OpenAlexW2325618528

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.